DOCSLIB.ORG

Driven by Our Promise™

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

CSL Limited Limited CSL Annual Report 2019/20 Driven by Our Promise™ CSL Limited Annual Report 2019/20 Contents 1 Chairman and CEO Message 2 9 A Trusted Health Partner 37 2 2020 Performance 6 Product quality and safety 37 Business performance and highlights 6 Value and access 38 Financial highlights 7 Public policy engagement 38 3 Our Company 8 Infl uenza pandemic and emergency response 40 CSL at a glance 8 Relationships with patient groups 40 Our businesses 8 Responsible marketing and promotion 40 Our locations 9 Our expanding footprint 41 Our product portfolio 10 Ethical conduct 42 Our research and development pipeline 10 10 Promising Futures 44 4 Strategy and Performance 12 Diversity 44 Our 2030 strategy 12 Attraction and retention 45 How we create value 14 Training and development 46 United Nations sustainable development goals 16 Our employee-centric approach to COVID-19 46 Our fi nancial review 16 Employee engagement 46 Our operating review 16 Safety and wellbeing 47 Business strategies, prospects and likely developments 17 11 Our Communities 48 5 Our Material Risks 18 Our approach 48 Patient safety and product quality 18 Support for patient communities 49 Product innovation and competition 18 Support for biomedical communities 50 Supply, capacity and operations 18 Support for local communities 52 Market access 18 12 Governance 54 People and culture 19 Governance structure 54 Privacy and cybersecurity 19 Board composition 54 6 Outlook 20 Board of Directors 55 7 Powered by Innovation 21 Board committees 58 Expanding our R&D footprint 21 Leadership team 58 Investment in our R&D pipeline 21 Ethics and transparency 60 Strategic support for innovative medical research 24 Disclosure 60 Our drug delivery platforms 25 Corporate governance 60 Infl uenza vaccine technologies 26 Risk management 60 Addressing the global COVID-19 crisis 27 Tax transparency 60 New products to market 28 13 Financial Performance 61 Clinical trials in process and new 30 Directors’ Report 62 Innovation across the value chain 31 Auditor’s Independence Declaration 67 8 Global Reach and Impact 32 Consolidated Statement of Comprehensive Income 96 Global reach and focus 32 Consolidated Balance Sheet 97 Donor management 32 Consolidated Statement of Changes in Equity 98 Focus on effi ciency, standardised manufacturing 33 Consolidated Statement of Cash Flows 99 processes and integrated supply chain Notes to the Financial Statements 100 Secure and reliable supply 33 Directors’ Declaration 138 Environment, health and safety 34 Independent Auditor’s Report 139 14 Share Information 146 15 Medical Glossary 148 16 Key Performance Data Summary 150 CSL Calendar Annual General Meeting 2020 Key Dates 19 August Annual profi t and fi nal 2020 Annual General Meeting (AGM) of CSL Limited dividend announcement (ABN 99 051 588 348) will be held online on 10 September Shares traded ex-dividend Wednesday, 14 October 2020 at 10 am (Melbourne time). 11 September Record date for fi nal dividend 9 October Final dividend paid 14 October Annual General Meeting 31 December Half Year ends Find out more 2021 Key Dates CSL.com 16 February Half year profi t and interim dividend announcement 4 March Shares traded ex-dividend About this report 5 March Record date for interim dividend This is CSL’s second annual report where we have combined our 1 April Interim dividend paid financial and non-financial performance in one comprehensive 30 June Full Year ends account, linking our sustainability and strategic priorities to our business results. Unless otherwise stated, this report covers CSL’s 18 August Annual profi t and fi nal subsidiaries as listed on Note 17 of the Financial Statements. In 2019/20, dividend announcement we concluded our fourth materiality assessment. Our prioritised 2 September Shares traded ex-dividend topics are listed on page 15 and detailed throughout the Report. 3 September Record date for fi nal dividend In addition to an independent audit of our consolidated financial accounts, limited assurance on a selection of corporate responsibility 30 September Final dividend paid (CR) metrics has been provided by Ernst & Young, and an assurance 12 October Annual General Meeting statement for non-fi nancial indicators, along with more detailed 31 December Half Year ends Group and CR information, including our materiality assessment, can be found on CSL.com (Our Company > Corporate Responsibility). Read Sam’s story on page 42 The people and science of CSL save lives. We develop and deliver innovative medicines that help people with serious and life- threatening conditions live full lives and protect the health of communities around the world. Our Values guide us in creating sustainable value for our stakeholders. Read Stacy’s story on page 28 CSL Limited Annual Report 2020 1 1 Chairman and CEO Message US$2,103 million in reported net profit after tax. US$2.02 dividend per share for 2020. Dear Stakeholders, In writing this message we have had the opportunity to reflect This decision was made following a strategic review and will on the sobering and far-reaching impact that the COVID-19 allow us to access capabilities from an experienced partner pandemic has had on our global community. and leverage our own internal investments. While the pandemic has certainly added complexity to our While some clinical trial stage programs in our research business and operating environment, CSL has had a number portfolio have been slowed due to COVID-19, our Phase 3 of notable achievements throughout the year, including program investigating CSL112 for reduction of recurrent the Company’s 25th anniversary as a listed company on cardiovascular events is progressing well. Over 9,500 patients the Australian Securities Exchange. We are pleased to share are now recruited and the results of a futility analysis have some of those success stories in this report. provided us the confidence to continue as planned. Business Highlights As we’ve seen with the recent registration of Flucelvax in Europe, Seqirus continues to go from strength to strength CSL has continued to deliver value to shareholders because as its differentiated product portfolio gains a strong of our unwavering focus on delivering innovative products reputation in global markets. to people with rare and serious disease, and to protecting the health of the public with our influenza vaccines portfolio. Our relationships with the biomedical community have always been critical to the way we approach our innovation This year we made a series of investments designed to portfolio. In planning for future growth, we made the decision strengthen the next-generation therapeutic areas within our to build a bespoke facility to house our Company’s Australian portfolio. We exercised an option to fully acquire biotechnology headquarters and expand our R&D footprint with a new company Vitaeris, specifically its late-stage monoclonal 16-storey building in the heart of Melbourne’s biomedical antibody therapy to address long-term rejection in kidney precinct. It will accommodate 800 employees from 2024. transplants. Additionally, subject to receiving regulatory The move ensures we are well placed to strengthen our approval we acquired the exclusive global license rights to partnerships and deepen the valuable relationships we have commercialise a Phase 3 stage program adeno-associated virus with the local biomedical community. The move will also (AAV) gene therapy program for the treatment of haemophilia bring key elements of our Australian operations together, B from uniQure, an asset that if successful will prove fostering stronger internal collaboration. transformational for patients suffering this disease. Expanding our stem cell gene therapy portfolio, we established an alliance With our robust research and development (R&D) pipeline, with Seattle Children’s Research Institute to develop stem Commercial and Operations excellence, passionate people cell gene therapies for primary immunodeficiency diseases. and global reputation as a leading biotechnology company, we have delivered a strong result for the year. It reflects the We also entered into a long-term strategic partnership with focused execution of our strategy, robust demand for our Thermo Fisher Scientific for the lease of our state-of-the-art differentiated medicines and our commitment for meeting biotech manufacturing facility currently under construction the needs of people who rely on our therapies. in Lengnau, Switzerland. When construction is complete, Thermo Fisher will lease and operate the Lengnau facility We are pleased to deliver a record dividend to shareholders and provide production support for CSL’s biologics portfolio. of US$2.02 per share for 2020. 2 CSL Limited Annual Report 2020 Unified by our Values Throughout the pandemic period, the majority of our We remain optimistic that the extraordinary amount of employees have continued to work on our sites and in our scientific collaboration happening across industry, academia laboratories carrying out roles that are critical to ensuring and government, including many initiatives we are proud our business continuity. to be a part of, will lead to effective treatments and vaccines in the near future. Until that time, we are greatly encouraged For many others in our workforce, it has meant working by the fast adjustments that our business has been able to remotely and adopting new technologies to ensure our make to adapt to changing conditions, and help us endure culture of collaboration continues as we prepare for the any impacts of the pandemic. safe return to our office sites. We are confident that from the pandemic crisis, society will Through this challenging environment, our employees have eventually discover many benefits arising from it, ranging stayed focused while demonstrating creativity, flexibility and across the acceleration and adoption of new technologies, resilience in continuing to do their jobs and doing them well. a deep resilience and ability to recover by the community, Our people remain unified by our Values of Patient Focus, and a significant contribution to science and medicine.
Recommended publications
  • CSL Behring Letterhead Template

    CSL Behring Letterhead Template

    AFSTYLA®, for Haemophilia A, Receives Positive Opinion from European Medicines Agency CHMP MARBURG, Germany — 14 November 2016 CHMP positive opinion moves AFSTYLA one step closer to approval in the European Union AFSTYLA is the first and only single-chain therapy for haemophilia A. The therapy has been specifically designed for greater molecular stability and duration of action through strong affinity to von Willebrand factor (VWF) AFSTYLA has been shown to offer excellent haemostatic efficacy in both prophylaxis and on-demand treatment, and the option of twice weekly dosing with low unit consumption Global biotherapeutics leader CSL Behring announced today that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation for AFSTYLA® [Recombinant Human Coagulation Factor VIII, Single Chain] for patients with haemophilia A. AFSTYLA, CSL Behring’s novel, recombinant factor VIII therapy for adults and children, is the first and only single-chain product for haemophilia A. It is specifically designed for protection from bleeds with two or three times weekly dosing and low unit consumption at both dosing regimens. In clinical trials, AFSTYLA demonstrated a strong safety profile with no inhibitors observed in previously treated patients undergoing prophylaxis. “For 100 years, CSL has focused on researching and developing innovative therapies that meet the treatment challenges patients face,” said Dr. Andrew Cuthbertson, Chief Scientific Officer and R&D Director, CSL Limited. “CHMP’s positive opinion for AFSTYLA® moves us one step closer to bringing this novel treatment option to haemophilia A patients in the European Union. Once approved, AFSTYLA will provide adults and children with a therapy that delivers on our promise to develop and bring to market innovative specialty biotherapies that help patients live full lives.” About Haemophilia A Primarily affecting males, haemophilia A is a congenital bleeding disorder characterised by deficient or defective factor VIII.
  • MONONINE (“Difficulty ® Monoclonal Antibody Purified in Concentrating”; Subject Recovered)

    MONONINE (“Difficulty ® Monoclonal Antibody Purified in Concentrating”; Subject Recovered)

    CSL Behring IU/kg (n=38), 0.98 ± 0.45 K at doses >95-115 IU/kg (n=21), 0.70 ± 0.38 K at doses >115-135 IU/kg (n=2), 0.67 K at doses >135-155 IU/kg (n=1), and 0.73 ± 0.34 K at doses >155 IU/kg (n=5). Among the 36 subjects who received these high doses, only one (2.8%) Coagulation Factor IX (Human) reported an adverse experience with a possible relationship to MONONINE (“difficulty ® Monoclonal Antibody Purified in concentrating”; subject recovered). In no subjects were thrombo genic complications MONONINE observed or reported.4 only The manufacturing procedure for MONONINE includes multiple processing steps that DESCRIPTION have been designed to reduce the risk of virus transmission. Validation studies of the Coagulation Factor IX (Human), MONONINE® is a sterile, stable, lyophilized concentrate monoclonal antibody (MAb) immunoaffinity chromatography/chemical treatment step and of Factor IX prepared from pooled human plasma and is intended for use in therapy nanofiltration step used in the production of MONONINE doc ument the virus reduction of Factor IX deficiency, known as Hemophilia B or Christmas disease. MONONINE is capacity of the processes employed. These studies were conducted using the rel evant purified of extraneous plasma-derived proteins, including Factors II, VII and X, by use of enveloped and non-enveloped viruses. The results of these virus validation studies utilizing immunoaffinity chromatography. A murine monoclonal antibody to Factor IX is used as an a wide range of viruses with different physicochemical properties are summarized in Table affinity ligand to isolate Factor IX from the source material.
  • (Human) Monoclate-P® Factor VIII: C Pasteurized Monoclonal Antibody Purified

    (Human) Monoclate-P® Factor VIII: C Pasteurized Monoclonal Antibody Purified

    CSL Behring 1020 First Avenue PO Box 61501 King of Prussia, PA 19406-0901 Tel 610-878-4000 March 2018 Important availability information for Antihemophilic Factor (Human) Monoclate-P® Factor VIII: C Pasteurized Monoclonal Antibody Purified Dear Valued Customer: Throughout CSL Behring’s long history of providing leading hemophilia treatments, we have offered a broad portfolio of products, including Antihemophilic Factor (Human) Monoclate- P® Factor VIII:C Pasteurized Monoclonal Antibody Purified. We are writing now to keep you updated about product availability. CSL Behring has made the difficult decision to discontinue Monoclate-P and we estimate that supply will be available through December 2018, giving you time to consider your patients’ treatment options. Please note that due to expiration dating, availability of the 1500 IU vial size may be limited. We recognize that Monoclate-P has been an important part of your patients’ lives, and we remain committed to keeping you informed so you can appropriately advise them. We also want to share the rationale behind this decision. As hemophilia A treatment has advanced, and patients have transitioned from plasma-derived to recombinant and longer-acting therapies, it has been increasingly difficult to sustain the production and distribution of Monoclate-P. We encourage your Monoclate-P patients to speak with their physician regarding treatment options. As a patient-focused company, CSL Behring strives to create innovative therapies for the hemophilia community. That’s why we will continue to offer two therapies, AFSTYLA®, Antihemophilic Factor (Recombinant), Single Chain, a next-generation Factor VIII therapy, and plasma-derived Antihemophilic Factor/von Willebrand Factor Complex (Human), Humate-P®.
  • Westpac Online Investment Loan Acceptable Securities List - Effective 3 September2021

    Westpac Online Investment Loan Acceptable Securities List - Effective 3 September2021

    Westpac Online Investment Loan Acceptable Securities List - Effective 3 September2021 ASX listed securities ASX Code Security Name LVR ASX Code Security Name LVR A2M The a2 Milk Company Limited 50% CIN Carlton Investments Limited 60% ABC Adelaide Brighton Limited 60% CIP Centuria Industrial REIT 50% ABP Abacus Property Group 60% CKF Collins Foods Limited 50% ADI APN Industria REIT 40% CL1 Class Limited 45% AEF Australian Ethical Investment Limited 40% CLW Charter Hall Long Wale Reit 60% AFG Australian Finance Group Limited 40% CMW Cromwell Group 60% AFI Australian Foundation Investment Co. Ltd 75% CNI Centuria Capital Group 50% AGG AngloGold Ashanti Limited 50% CNU Chorus Limited 60% AGL AGL Energy Limited 75% COF Centuria Office REIT 50% AIA Auckland International Airport Limited 60% COH Cochlear Limited 65% ALD Ampol Limited 70% COL Coles Group Limited 75% ALI Argo Global Listed Infrastructure Limited 60% CPU Computershare Limited 70% ALL Aristocrat Leisure Limited 60% CQE Charter Hall Education Trust 50% ALQ Als Limited 65% CQR Charter Hall Retail Reit 60% ALU Altium Limited 50% CSL CSL Limited 75% ALX Atlas Arteria 60% CSR CSR Limited 60% AMC Amcor Limited 75% CTD Corporate Travel Management Limited ** 40% AMH Amcil Limited 50% CUV Clinuvel Pharmaceuticals Limited 40% AMI Aurelia Metals Limited 35% CWN Crown Limited 60% AMP AMP Limited 60% CWNHB Crown Resorts Ltd Subordinated Notes II 60% AMPPA AMP Limited Cap Note Deferred Settlement 60% CWP Cedar Woods Properties Limited 45% AMPPB AMP Limited Capital Notes 2 60% CWY Cleanaway Waste
  • Insurance Australia Group Annual Report 2015 Insurance Australia Group Annual Report 2015

    Insurance Australia Group Annual Report 2015 Insurance Australia Group Annual Report 2015

    Insurance Australia Group Annual Report 2015 Insurance Australia Group Annual Report 2015 INSURANCE AUSTRALIA GROUP LIMITED ABN 60 090 739 923 CONTENTS Five year financial summary 1 Directors’ declaration 98 Directors’ report 2 Independent auditor’s report 99 Remuneration report 16 Shareholder information 101 Lead auditor’s independence declaration 36 Corporate directory 104 Financial statements 37 KEY DATES 2015 financial year end 30 June 2015 Full year results and dividend announcement 21 August 2015 Notice of meeting mailed to shareholders 7 September 2015 Final dividend for ordinary shares Record date 9 September 2015 Payment date 7 October 2015 Annual general meeting 21 October 2015 Half year end 31 December 2015 Half year results and dividend announcement 18 February 2016* Interim dividend for ordinary shares Record date 2 March 2016* * Payment date 30 March 2016 2016 financial year end 30 June 2016 Full year results and dividend announcement 19 August 2016* * Please note: dates are subject to change. Any changes will be published via a notice to the Australian Securities Exchange (ASX) 2015 Annual About this report General Meeting The 2015 annual report of Insurance Australia Group Limited (IAG, or IAG’s 2015 annual general meeting will the Group) includes IAG’s full statutory be held on Wednesday, 21 October 2015, accounts, along with the Directors’ and at the City Recital Hall, Angel Place remuneration reports for the financial Sydney, commencing at 10.00am. Details year 2015. This year’s corporate governance of the meeting, including information report is available in the About Us area of about how to vote, will be contained our website (www.iag.com.au).
  • Macquarie Alternative Listed Protected Securities – APSSM3

    Macquarie Alternative Listed Protected Securities – APSSM3

    Macquarie Bank Limited ABN 46 008 583 542 Equity Markets Group No. 1 Martin Place Telex 122246 Telephone (61 2) 8232 3333 Sydney NSW 2000 DX 10287 SSE Facsimile (61 2) 8232 6882 GPO Box 3423 SWIFT MACQAU2S Internet http://www.macquarie.com.au Sydney NSW 1164 Group Offices in Hong Kong, London, Sao Paulo and Tokyo 16 August 2005 Wayne Elliott ASX Derivatives Level 6, 20 Bridge Street Sydney NSW 2000 Dear Wayne For announcement to the market: Macquarie Alternative Listed Protected Securities – APSSM3 Macquarie Bank Limited (“Macquarie”) is the issuer of Alternative Listed Protected Securities Series 3 (“ALPS”) (ASX code: APSSM3) pursuant to a Product Disclosure Statement dated 17 May 2005 which is linked to a Reference Basket of 80 Securities. The Initial Price for each Security is determined as the arithmetic average of the Volume Weighted Average Price for each of the 5 Trading Days up to and including the Start Date (15 August 2005). The Knockout Price for each Security is determined as 55% of the Initial Price. Macquarie advises the Initial Price and Knockout Price for each of the Securities in the Reference Basket as follows: ASX Knockout Code Company Initial Price Price ABS A.B.C. Learning Centres Limited $5.6233 $3.0928 ALL Aristocrat Leisure Limited $13.2042 $7.2623 AMC Amcor Limited $7.0337 $3.8685 AMP AMP Limited $6.8524 $3.7688 ANN Ansell Limited $9.8791 $5.4335 ASX Australian Stock Exchange Limited $25.6753 $14.1214 AWC Alumina Limited $6.1068 $3.3587 AXA AXA Asia Pacific Holdings Limited $4.5173 $2.4845 BBG Billabong International Limited $13.6304 $7.4967 BHP BHP Billiton Limited $20.6501 $11.3576 BIL Brambles Industries Limited $8.6271 $4.7449 BLD Boral Limited.
  • CSL Limited Annual Report

    CSL Limited Annual Report

    CSL Limited Limited CSL CSL Limited Annual Report Annual Report 2017/18 2017/18 Driven by Our Promise™ Contents 02 About CSL 04 Our Businesses AGM NEW TIME YEAR IN REVIEW AND VENUE! 06 Key Business Highlights 08 Financial Highlights ANNUAL GENERAL MEETING 2018 10 Year in Review Wednesday, 17 October 2018 at 1pm 15 August Annual profit and final dividend Clarendon Auditorium announcement BUSINESS PROFILES Melbourne Convention and Exhibition Centre 11 September Shares traded ex-dividend 20 CSL Behring (MCEC), South Wharf, Melbourne 3000 12 September Record date for final dividend 28 Seqirus AGM LIVE WEBCAST 32 Research and Development 12 October Final dividend paid The CSL Limited Annual General Meeting will be 17 October Annual General Meeting OUR COMPANY webcast through CSL’s website CSL.com 31 December Half year ends 36 Directors Log on to the home page of CSL’s website and 38 Global Leadership Group then click on the item called Annual General 2019 40 Share Information Meeting webcast. 41 Shareholder Information 13 February Half year profit and interim dividend announcement 43 Corporate Governance at CSL SHARE REGISTRY 13 March Shares traded ex-dividend Computershare Investor Services Pty Limited FINANCIAL REPORT 14 March Record date for interim dividend Yarra Falls, 452 Johnston Street 46 Directors’ Report 12 April Interim dividend paid 54 Auditor’s Independence Declaration Abbotsford VIC 3067 30 June Year ends 77 Consolidated Statement of Postal Address: GPO Box 2975 14 August Annual profit and final dividend Comprehensive Income Melbourne
  • IAG Annual Report 2014

    IAG Annual Report 2014

    Insurance Australia Annual Group Report 2014 Insurance Australia Group Annual Report 2014 THE NUMBERS INSURANCE AUSTRALIA GROUP LIMITED ABN 60 090 739 923 CONTENTS Five year financial summary 1 Financial statements 49 Corporate governance 2 Directors’ declaration 117 Directors’ report 12 Independent auditor’s report 118 Remuneration report 26 Shareholder information 120 Lead auditor’s independence declaration 48 Corporate directory 124 KEY DATES 2014 financial year end 30 June 2014 Full year results and dividend announcement 19 August 2014 Notice of meeting mailed to shareholders 8 September 2014 Final dividend for ordinary shares Record date 10 September 2014 Payment date 8 October 2014 Annual General Meeting 30 October 2014 Half year end 31 December 2014 Half year results and dividend announcement 20 February 2015* Interim dividend for ordinary shares Record date 4 March 2015* Payment date 1 April 2015* 2015 financial year end 30 June 2015 Full year results and dividend announcement 21 August 2015* * Please note: dates are subject to change. Any changes will be published via a notice to the Australian Securities Exchange 2014 ANNUAL 2014 ANNUAL RECYCLED GENERAL MEETING REPORT SUITE PAPER CHOICE IAG’s 2014 annual general meeting The 2014 annual report of Insurance This report is printed on Nordset an will be held on Thursday, 30 October Australia Group Limited (IAG, or the Group) environmentally responsible paper produced 2014, at the Wesley Conference Centre, includes IAG’s full statutory accounts, from FSC® Mixed Sources Chain of Custody 220 Pitt Street, Sydney NSW 2000, along with the Directors’, remuneration (CoC) certified pulp from well managed commencing at 10.00am.
  • ESG Reporting by the ASX200

    ESG Reporting by the ASX200

    Australian Council of Superannuation Investors ESG Reporting by the ASX200 August 2019 ABOUT ACSI Established in 2001, the Australian Council of Superannuation Investors (ACSI) provides a strong, collective voice on environmental, social and governance (ESG) issues on behalf of our members. Our members include 38 Australian and international We undertake a year-round program of research, asset owners and institutional investors. Collectively, they engagement, advocacy and voting advice. These activities manage over $2.2 trillion in assets and own on average 10 provide a solid basis for our members to exercise their per cent of every ASX200 company. ownership rights. Our members believe that ESG risks and opportunities have We also offer additional consulting services a material impact on investment outcomes. As fiduciary including: ESG and related policy development; analysis investors, they have a responsibility to act to enhance the of service providers, fund managers and ESG data; and long-term value of the savings entrusted to them. disclosure advice. Through ACSI, our members collaborate to achieve genuine, measurable and permanent improvements in the ESG practices and performance of the companies they invest in. 6 INTERNATIONAL MEMBERS 32 AUSTRALIAN MEMBERS MANAGING $2.2 TRILLION IN ASSETS 2 ESG REPORTING BY THE ASX200: AUGUST 2019 FOREWORD We are currently operating in a low-trust environment Yet, safety data is material to our members. In 2018, 22 – for organisations generally but especially businesses. people from 13 ASX200 companies died in their workplaces. Transparency and accountability are crucial to rebuilding A majority of these involved contractors, suggesting that this trust deficit. workplace health and safety standards are not uniformly applied.
  • Joint Submission to the Inquiry Into Impediments to Business

    Joint Submission to the Inquiry Into Impediments to Business

    CSL biopharmaceutical manufacturing Broadmeadows, Victoria Cochlear medical device manufacturing Macquarie University, NSW Joint Submission to the House of Representatives Standing Committee on Economics Inquiry into Impediments to Business Investment May 2018 1 Executive Summary CSL and Cochlear are Australian success stories. They are the nation’s two largest and most successful innovation-focussed advanced manufacturing companies, both actively and successfully competing globally from an Australian base. Innovation and Science Australia’s recently released 2030 Strategic Plan predicted that Australia’s future prosperity will need to be driven by knowledge intensive companies that collaborate, innovate and export – companies like CSL and Cochlear. However, in 2017 CSL and Cochlear were two of only four Australian companies to make the list of the world’s top 1000 global R&D spenders1 both with an R&D intensity of over 10 per cent. Cochlear has over 100 research partnerships across the world and CSL has more than 180 in Australia alone. Both companies have a strong interest in enhancing Australia’s international competitiveness and maximising the social and economic benefits flowing from innovation- focussed industries but competition among peer nations for advanced manufacturing and R&D is intense. Policy makers all over the world are actively using micro and macro-economic levers to poach and fiercely compete for skilled job-creating capital investments. The realities are stark - less than 5% of Cochlear’s sales revenue is from Australia but it pays over 73% of its total tax bill here. For CSL, Australian sales revenue represents less than 10% of global external sales revenue, and its global income taxes (US$468.3 million paid in 2017) are paid in the countries where the majority of taxable income is earned.
  • RIASTAP®, Fibrinogen Concentrate (Human) Lyophilized Powder for Solution for Intravenous Injection

    RIASTAP®, Fibrinogen Concentrate (Human) Lyophilized Powder for Solution for Intravenous Injection

    HIGHLIGHTS OF PRESCRIBING INFORMATION -------------------------------------CONTRAINDICATIONS ------------------------------------ These highlights do not include all the information needed to use RIASTAP • Known anaphylactic or severe systemic reactions to human plasma-derived products (4). safely and effectively. See full prescribing information for RIASTAP. ---------------------------------WARNINGS AND PRECAUTIONS---------------------------- RIASTAP®, Fibrinogen Concentrate (Human) • Monitor patients for early signs of anaphylaxis or hypersensitivity reactions and if necessary, discontinue administration and institute appropriate treatment (5.1). Lyophilized Powder for Solution for Intravenous Injection • Thrombotic events have been reported in patients receiving RIASTAP. Weigh the benefits of administration versus the risks of thrombosis (5.2). Initial U.S. Approval: 2009 • Because RIASTAP is made from human blood, it may carry a risk of transmitting ------------------------------------RECENT MAJOR CHANGES--------------------------------- infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent Indications and Usage (1) 06/2021 and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent (5.3). Dosage and Administration (2.2) 07/2020 -------------------------------------ADVERSE REACTIONS-------------------------------------- ----------------------------------INDICATIONS AND USAGE----------------------------------- • The most serious adverse reactions observed are thrombotic episodes (pulmonary RIASTAP, Fibrinogen
  • Design, Project Management, Operations and Maintenance”

    Design, Project Management, Operations and Maintenance”

    Facilities Management “Design, Project Management, Operations and Maintenance” Concise Annual Report 2003 Downer EDI Limited (Downer EDI) is an Australian listed company which provides comprehensive engineering and infrastructure management services to the public and private power, rail, road, telecommunications, mining and minerals processing sectors. It employs more than 15,000 people and its services cover Australia, New Zealand, Asia and the Pacific. “Downer EDI is one of the few fully integrated engineering and infrastructure management companies in the Asia Pacific region able to provide services to clients in the transportation, power, telecommunications, mining and energy sectors.” 01 Agm Downer EDI’s business consists of Downer EDI Limited’s 2003 The Downer EDI Limited 2003 Concise four principal activities: Annual General Meeting will be Annual Report reflects the activity of held in Sydney at The Heritage Downer EDI Limited for the financial Infrastructure Ballroom, The Westin Hotel, year 1 July 2002 to 30 June 2003. Road build and maintenance 1 Martin Place, Sydney on Australian dollars, unless otherwise Rail track build and maintenance 27 October 2003 commencing stated, is the standard currency used 10.00 am. All shareholders are throughout this Report. Engineering invited to attend and are entitled The Concise Annual Report provides Design and facilities management to be present. a summary of Downer EDI Limited’s Telecommunications build and Shareholders who are unable to attend financial performance, financial position, maintenance the Annual General Meeting, but and operating, investing and financing Power build and maintenance choose to vote on the proposed activities. Detailed financial information resolutions, are encouraged to for Downer EDI Limited for the year Mining complete a proxy form and lodge it ended 30 June 2003 is set out in the Operation and infrastructure at least 48 hours prior to the meeting.